UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institution-specific guideline

Transplant infectious disease, 2011-04, Vol.13 (2), p.117-121

2011

Volltextzugriff (PDF)

Prevention of Peritransplantation Viridans Streptococcal Bacteremia with Early Vancomycin Administration: A Single-Center Observational Cohort Study

Clinical infectious diseases, 2004-12, Vol.39 (11), p.1625-1632

2004

Volltextzugriff (PDF)

Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institutionaspecific guideline

Transplant infectious disease, 2011-04, Vol.13 (2), p.117-121

2011

Volltextzugriff (PDF)

Treatment of Respiratory Syncytial Virus Infection in Adult Patients with Hematologic Malignancies on An Institution-Specific Guideline

Biology of blood and marrow transplantation, 2009-02, Vol.15 (2), p.93-93

2009

Volltextzugriff (PDF)

Targeting protein tyrosine phosphatases for anticancer drug discovery

Current pharmaceutical design, 2010-06, Vol.16 (16), p.1843-1862

2010

Volltextzugriff (PDF)

GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

Nature communications, 2018-12, Vol.9 (1), p.5154-9, Article 5154

2018

Volltextzugriff (PDF)

A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation

Cancer research (Chicago, Ill.), 2013-03, Vol.73 (6), p.1922-1933

2013

Volltextzugriff (PDF)

Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities

Oncogene, 2014-01, Vol.33 (5), p.550-555

2014

Volltextzugriff (PDF)

Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

Proceedings of the National Academy of Sciences - PNAS, 2007-05, Vol.104 (18), p.7391-7396

2007

Volltextzugriff (PDF)

Development of o‑Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors

Journal of medicinal chemistry, 2012-09, Vol.55 (17), p.7392-7416

2012

Volltextzugriff (PDF)

Discovery of JSI-124 (cucurbitacin I), a selective janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice

Cancer research (Chicago, Ill.), 2003-03, Vol.63 (6), p.1270-1279

2003

Volltextzugriff (PDF)

Loss of Bif-1 Suppresses Bax/Bak Conformational Change and Mitochondrial Apoptosis

Molecular and Cellular Biology, 2005-11, Vol.25 (21), p.9369-9382

2005

Volltextzugriff (PDF)

Inhibitors of Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (Shp2) Based on Oxindole Scaffolds

Journal of medicinal chemistry, 2008-08, Vol.51 (16), p.4948-4956

2008

Volltextzugriff (PDF)

Oxadiazole-isopropylamides as Potent and Noncovalent Proteasome Inhibitors

Journal of medicinal chemistry, 2013-05, Vol.56 (10), p.3783-3805

2013

Volltextzugriff (PDF)

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt

Cancer research (Chicago, Ill.), 2004-07, Vol.64 (13), p.4394-4399

2004

Volltextzugriff (PDF)

Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity

Oncogene, 2005-05, Vol.24 (20), p.3236-3245

2005

Volltextzugriff (PDF)

Discovery and Synthesis of Hydronaphthoquinones as Novel Proteasome Inhibitors

Journal of medicinal chemistry, 2012-03, Vol.55 (5), p.1978-1998

2012

Volltextzugriff (PDF)

Lysophosphatidic acid acyltransferase beta regulates mTOR signaling

PloS one, 2013, Vol.8 (10), p.e78632-e78632

2013

Volltextzugriff (PDF)

Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma

Journal of clinical oncology, 2011-06, Vol.29 (17), p.2350-2356

2011

Volltextzugriff (PDF)

Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells

Nature communications, 2015-07, Vol.6 (1), p.7629-7629, Article 7629

2015

Volltextzugriff (PDF)

Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors

Bioorganic & medicinal chemistry, 2010-08, Vol.18 (15), p.5576-5592

2010

Volltextzugriff (PDF)

Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors

Clinical cancer research, 2019-10, Vol.25 (19), p.5984-5996

2019

Volltextzugriff (PDF)

Discovery of a Novel Shp2 Protein Tyrosine Phosphatase Inhibitor

Molecular pharmacology, 2006-08, Vol.70 (2), p.562-570

2006

Volltextzugriff (PDF)

Discovery of PI-1840, a Novel Noncovalent and Rapidly Reversible Proteasome Inhibitor with Anti-tumor Activity

The Journal of biological chemistry, 2014-04, Vol.289 (17), p.11906-11915

2014

Volltextzugriff (PDF)

Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies

Clinical cancer research, 2009-11, Vol.15 (22), p.7061-7068

2009

Volltextzugriff (PDF)

1 – 25 von 213

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(188)
Mit Volltextzugriff
(186)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institution-specific guideline

Prevention of Peritransplantation Viridans Streptococcal Bacteremia with Early Vancomycin Administration: A Single-Center Observational Cohort Study

Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institutionaspecific guideline

Treatment of Respiratory Syncytial Virus Infection in Adult Patients with Hematologic Malignancies on An Institution-Specific Guideline

Targeting protein tyrosine phosphatases for anticancer drug discovery

GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation

Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities

Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

Development of o‑Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors

Discovery of JSI-124 (cucurbitacin I), a selective janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice

Loss of Bif-1 Suppresses Bax/Bak Conformational Change and Mitochondrial Apoptosis

Inhibitors of Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (Shp2) Based on Oxindole Scaffolds

Oxadiazole-isopropylamides as Potent and Noncovalent Proteasome Inhibitors

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt

Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity

Discovery and Synthesis of Hydronaphthoquinones as Novel Proteasome Inhibitors

Lysophosphatidic acid acyltransferase beta regulates mTOR signaling

Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma

Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells

Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors

Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors

Discovery of a Novel Shp2 Protein Tyrosine Phosphatase Inhibitor

Discovery of PI-1840, a Novel Noncovalent and Rapidly Reversible Proteasome Inhibitor with Anti-tumor Activity

Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies

Suchergebnisse filtern